Category Archives: Press Release

The University of Colorado Anschutz Gates Institute has received Investigational New Drug clearance from the U.S. Food and Drug Administration, marking the first chimeric antigen receptor (CAR) T-cell therapy authorized for clinical testing that was developed entirely on the CU Anschutz campus.

ScaleReady Bio-Techne Corporation and CellReady announced that the Translational Sciences Laboratory at Gates Institute has been awarded a $300,000 G-Rex® Grant to develop a modular G-Rex centric CAR T-cell manufacturing platform.

Teams within the Gates Institute, including manufacturing, regulatory, and clinical trials support, came together to deliver this advanced therapy to a pediatric patient with leukemia.

The Gates Institute has appointed Michael Swabowski as its new director of operations for the Gates Biomanufacturing Facility (GBF).

When the Gates Biomanufacturing Facility opened its doors in 2015, cell and gene therapy (CGT) was just beginning to come into its own.

Lentiviral vector CDMO collaboration to support advanced cell therapies for hematological cancers. Written by Guest Contributor on June 25, 2024 Rockville, MD. – June 25, 2024 – Charles River Laboratories International, Inc. (NYSE: CRL) and the Gates Institute at the University of Colorado Anschutz Medical Campus today announced a lentiviral vector contract development and manufacturing organization (CDMO) agreement. Gates Institute will […]

Since receiving FDA approval in 2017, chimeric antigen receptor (CAR) T-cell therapy has shown remarkable success in treating patients with certain blood cancers such as lymphoma and leukemia.

Before we get to the thesis, I want to introduce you to the GBF. Our doors opened in 2015 as the current Good Manufacturing Practices

Enrollment has begun for a new phase 1 study of chimeric antigen receptor (CAR) T-cell therapy at UCHealth University of Colorado Hospital for adults with B-cell acute lymphoblastic leukemia (B-ALL). The trial is the first launched through the newly formed Gates Institute, and it will be the fourth for which the Gates Biomanufacturing Facility produces the CAR T product for research at CU Anschutz Medical Campus.

Enrollment has begun for a new phase 1 study of chimeric antigen receptor (CAR) T-cell therapy at UCHealth University of Colorado Hospital for adults with B-cell acute lymphoblastic leukemia (B-ALL). The trial is the first launched through the newly formed Gates Institute, and it will be the fourth for which the Gates Biomanufacturing Facility produces the CAR T product for research at CU Anschutz Medical Campus.